Skip to search formSkip to main contentSkip to account menu

fostamatinib

Known as: (6-((5-Fluoro-2-((3,4,5-Trimethoxyphenyl)Amino)Pyrimidin-4-yl)Amino)-2,2-Dimethyl-3-Oxo-2,3-Dihydro-4H-Pyrido(3,2-B)(1,4)Oxazin-4-Yl)Methyl Dihydrogen Phosphate, 2H-Pyrido(3,2-B)-1,4-Oxazin-3(4H)-One, 6-((5-Fluoro-2-((3,4,5-Trimethoxyphenyl)Amino)-4-Pyrimidinyl)Amino)-2,2-Dimethyl-4-((Phosphonooxy)Methyl)- 
A small molecule Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG… 
National Institutes of Health

Related topics

Related topics

4 relations
Fostamatinib DisodiumReceptor Tyrosine Kinase Inhibition

Broader (2)

OxazinesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
Oral fostamatinib is an orally administered small molecule spleen tyrosine kinase (SYK) inhibitor approved for the treatment of… 
2015
2015
The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
OBJECTIVES Spleen tyrosine kinase (SYK) is a core signalling protein that drives inflammatory responses and is fundamental to the… 
2015
2015
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia…
BCR signaling pathway inhibitors such as ibrutinib, idelalisib, and fostamatinib (respective inhibitors of Bruton’s tyrosine… 
2015
2015
Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents
Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase which has completed clinical trials for… 
2014
2014
Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia
Pre-BCR–independent activation of spleen tyrosine kinase plays a pathogenic role in high-risk B cell acute lymphoblastic leukemia… 
2014
2014
SYK inhibition in experimental autoimmune vasculitis and its glomerular expression in ANCA-associated vasculitis
Review
2013
Review
2013
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
The pathogenesis of RA is a complex and ever-changing landscape but amid the chaos of the disease process we have found effective… 
2012
2012
The status of fostamatinib in the treatment of rheumatoid arthritis
Fostamatinib (R788) is a prodrug rapidly converted to its active metabolite on oral administration. This (known as R406) is a… 
2011
2011
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
Review
2010
Review
2010
Signal transduction inhibitor therapy for lymphoma.
Current research in lymphoma is focused on two areas of lymphoma biology-the signal transduction pathways used to maintain the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)